Vitamin D in Patients with Kidney Disease: Cautiously Optimistic

Advances in Chronic Kidney Disease

Volumn 14, Issue 1, 2007, Pages 22-26

  Thadhani, Ravi ^a   Wolf, Myles ^a  

^a Center for D receptor Activation Research   (United States)

Author keywords

Cardiovascular disease; Hemodialysis survival; Vitamin D

Indexed keywords

PARATHYROID HORMONE; VITAMIN D; VITAMIN D RECEPTOR;

ARTICLE; BONE; CARDIOVASCULAR FUNCTION; CHRONIC KIDNEY DISEASE; HEMODIALYSIS; HOMEOSTASIS; HUMAN; INTESTINE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PARATHYROID GLAND; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; UREMIA; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

HUMANS; KIDNEY DISEASES; RENAL DIALYSIS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 33845872000     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2006.10.009     Document Type: Article

References (38)

1. Dusso A.S. Vitamin D receptor: Mechanisms for vitamin D resistance in renal failure. Kidney Int Suppl 85 (2003) 6-9
2. Brown A.J. Therapeutic uses of vitamin D analogues. Am J Kidney Dis 38 (2001) S3-S19
3. van Etten E., Branisteanu D., Verstuyf A., et al. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants. Transplantation 69 (2000) 1932-1942
4. Mathieu C., and Adorini L. The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med 8 (2002) 174-179
5. Makibayashi K., Mitsuyoshi T., Hirata M., et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 158 (2001) 1733-1741
6. O'Herrin J., Hullett D.A., Heisey D.M., et al. A retrospective evaluation of 1,25-dihydroxyvitamin D3 and its potential effects on renal allograft function. Am J Nephrol 22 (2002) 515-520
7. Nyomba B.L., Bouillon R., and De Moor P. Influence of vitamin D status on insulin secretion and glucose tolerance in the rabbit. Endocrinology 115 (1984) 191-197
8. Hypponen E., Laara E., Reunanen A., et al. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. Lancet 358 (2001) 1500-1503
9. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 92 (2006) 39-48
10. Zittermann A., Schleithoff S.S., and Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 94 (2005) 483-492
11. Li C., Kong J., Wei M., et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensis system. J Clin Invest 110 (2002) 229-238
12. Wu J., Garami M., Cheng T., et al. 1,25 (OH)2 vitamin D3 and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiomyocytes. J Clin Invest 97 (1996) 1577-1588
13. Watson K.E., Abrolat M.L., Malone L.L., et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96 (1997) 1755-1760
14. Zittermann A., Schleithoff S.S., Tenderich G., et al. Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure?. J Am Coll Cardiol 41 (2003) 105-112
15. Park C.W., Oh Y.S., Shin Y.S., et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 33 (1999) 73-81
16. Gonzalez E.A., Sachdeva A., Oliver D.A., et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 24 (2004) 503-510
17. Teng M., Wolf M., Lowrie E., et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349 (2003) 446-456
18. Thadhani R., and Tonelli M. Cohort studies: Marching forward. Clin J Am Soc Nephrol 1 (2006) 1117-1123
19. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16 (2005) 1115-1125
20. Cole S.R., Hernan M.A., Margolick J.B., et al. Marginal structural models for estimating the effect of highly active antiretroviral therapy initiation on CD4 cell count. Am J Epidemiol 162 (2005) 471-478
21. Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70 (2006) 771-800
22. Melamed M.L., Eustace J.A., Plantinga L., et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int 70 (2006) 351-357
23. LaClair R.E., Hellman R.N., Karp S.L., et al. Prevalence of calcidiol deficiency in CKD: A cross-sectional study across latitudes in the United States. Am J Kidney Dis 45 (2005) 1026-1033
24. Zehnder D., Bland R., Chana R.S., et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 13 (2002) 621-629
25. Zehnder D., Bland R., Williams M.C., et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 86 (2001) 888-894
26. Somjen D., Weisman Y., Kohen F., et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111 (2005) 1666-1671
27. Gallieni M., Kamimura S., Ahmed A., et al. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol 268 (1995) F746-F753
28. Norman A. Receptors for 1-alpha-25(OH)2D3: Past, presend and future. J Bone Miner Res 13 (1998) 1360-1369
29. Foley R.N., Parfrey P.S., Harnett J.D., et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47 (1995) 186-192
30. Hayashi S.Y., Rohani M., Lindholm B., et al. Left ventricular function in patients with chronic kidney disease evaluated by colour tissue Doppler velocity imaging. Nephrol Dial Transplant 21 (2006) 125-132
31. Zaslavsky L.M., Pinotti A.F., and Gross J.L. Diastolic dysfunction and mortality in diabetic patients on hemodialysis: A 4.25-year controlled prospective study. J Diabetes Complications 19 (2005) 194-200
32. Stack A.G., and Saran R. Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis 40 (2002) 1202-1210
33. Foley R.N., Parfrey P.S., Kent G.M., et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11 (2000) 912-916
34. Levin A., and Li Y.C. Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease?. Kidney Int 68 (2005) 1973-1981
35. Achinger S.G., and Ayus J.C. The role of vitamin D in left ventricular hypertrophy and cardiac function. Kidney Int Suppl 95 (2005) S37-S42
36. Rostand S.G., and Drueke T.B. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56 (1999) 383-392
37. Wolisi G.O., and Moe S.M. The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial 18 (2005) 307-314
38. Bas A., Lopez I., Perez J., et al. Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res 21 (2006) 484-490